Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
about
Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathwaysThe functional genomic response of developing embryonic submandibular glands to NF-kappa B inhibitionThe life cycle of chondrocytes in the developing skeleton.Fibroblast Growth Factor Signaling in Metabolic RegulationFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersThe 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognitionPKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.Genetic insights into the mechanisms of Fgf signalingInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationSixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasiasExposure to organophosphates reduces the expression of neurotrophic factors in neonatal rat brain regions: similarities and differences in the effects of chlorpyrifos and diazinon on the fibroblast growth factor superfamilyDefective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasiaInteraction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activationPreclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myelomaDNA damage response as a candidate anti-cancer barrier in early human tumorigenesisA place for precision medicine in bladder cancer: targeting the FGFRs.Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.ESCRT-II/Vps25 constrains digit number by endosome-mediated selective modulation of FGF-SHH signaling.Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilageIs fibroblast growth factor receptor 4 a suitable target of cancer therapy?The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesisLoss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancerGene disruption of Spred-2 causes dwarfism.The Fibroblast Growth Factor signaling pathwayIdentification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).Fibroblast growth factors in cancer: therapeutic possibilities.Role of genetic polymorphisms in tumour angiogenesisPLZF regulates fibroblast growth factor responsiveness and maintenance of neural progenitors.Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells.Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation.Anti-Angiogenic Properties of BDDPM, a Bromophenol from Marine Red Alga Rhodomela confervoides, with Multi Receptor Tyrosine Kinase Inhibition Effects.FGF signaling in the developing endochondral skeleton.ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3.Urothelial tumorigenesis: a tale of divergent pathways.MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transitionG388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.
P2860
Q24291107-22DC5D17-1A4B-40C2-87A0-4FDC33E43E7EQ24548250-D856903F-D975-45BA-93BC-980E4B5DB022Q24794871-2254477A-397D-4609-A872-5A290E2FEE6CQ24806072-F55A964C-B0DA-46A0-97AA-10ABDB99E510Q26772751-C5B50F24-ADDF-4A98-B189-394FB251FC5BQ26998955-286E9B72-DE31-4CCE-B3F7-510D76EE0B69Q27698320-4CAB3EC9-D7B7-45EE-B08E-C7F5A1C2FC9DQ27824821-00AE064F-E8CA-485A-974A-089338E6FDE4Q28066570-47AB6D32-D524-4875-9838-7F829FB01448Q28079309-BE79A5DD-F36E-4644-A2CF-234C01A7FFF6Q28252023-ADB55197-976B-4B0B-9875-9A9600D3CE21Q28395997-9FED55F7-80F9-47F4-A56F-7A08F4B6E8D9Q28508257-7E8D0108-C625-44B5-B24F-5D39CAFB44EDQ28592322-7CC8A7E7-7340-45AE-82D0-CDE93729EE51Q28678660-8BF1DDF5-229B-4256-894C-07176BC45245Q29614217-416B0331-EB80-4C07-B8B7-6BCC15E9D339Q30249143-588E5E1D-464D-4CA8-B270-3AF39F82A20CQ30491274-48A53301-D696-4327-BCBB-5E6DF89480ABQ30597083-3D0F5E44-3571-4EEE-83D5-520C302F00E9Q33273364-305CFC61-B618-4B7A-900C-F4E2BF8A7D41Q33393633-F23D7671-7FB6-4119-8936-45DB0E1DA355Q33751398-2E065EB4-205A-4C6A-AF37-2B6CEBB7DBC2Q33784827-964F128A-4F38-41E1-B4D2-AD1CBB42744EQ34102786-02129C22-4CC2-4C5F-9CAD-4B50875D54BCQ34358404-F23F5D40-4E2D-4A19-B625-2DFF230104CAQ34425218-6CBAD796-0DBD-42FB-8251-77420C9C6B59Q34467171-A6F7E286-1568-4106-9001-22424A43AA3CQ34733600-41438976-A4EE-462D-A84D-A24F37EB26AAQ34837255-A86C5193-1E05-4D5F-AC77-3E0BE8933685Q34981278-76820B23-B8B3-40DA-8BE0-2AC611735D14Q35014263-07A3DD39-05FE-47AF-BCC2-C78054A1328FQ35669841-9E3B1862-8796-4811-962D-41C5E29B0E99Q35683608-442EF62D-5C61-4927-88CA-EA72B5025418Q35814050-C384B1E1-24B3-464C-BF13-ABEC77D65A5AQ36111408-885775DB-7543-4D00-B1F9-9E89F4EEC1DAQ36141386-5AACA333-10D0-48C7-9BDE-442A76150F5FQ36234720-371DAB33-CFCF-43C3-AD4E-5826FCC55B16Q36546530-6B9B28E1-8283-4B9A-A2B8-7F53E47999C8Q36673626-D73B33DB-BF66-45B9-A19C-6FA5C217EC22Q36707108-B6AF14E3-3378-4E44-8120-A65724D89EC5
P2860
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@ast
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en-gb
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@nl
type
label
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@ast
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en-gb
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@nl
prefLabel
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@ast
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en-gb
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@nl
P2093
P2860
P3181
P356
P1433
P1476
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
@en
P2093
D J Donoghue
M Y Kanemitsu
S C Robertson
P2860
P2888
P304
P3181
P356
10.1038/SJ.ONC.1203650
P407
P577
2000-07-06T00:00:00Z
P5875
P6179
1006401110